Cancer-Therapy-Related Adverse Events (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 1 September 2026 | Viewed by 76

Special Issue Editors


E-Mail Website
Guest Editor
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: cancer immunotherapy-related GI toxicity; colitis; inflammatory bowel disease; fecal microbiota transplantation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
The Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA
Interests: cancer care; cancer therapy; toxicities
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of “Cancer-Therapy-Related Adverse Events”.

We invite you to contribute to this Special Issue on cancer-therapy-related adverse events in different organ systems. With new cancer treatment strategies rapidly emerging, we recognize the limitations of and the need to expand the knowledge on toxicity management. These hurdles frequently disrupt cancer treatments and compromise patient outcomes. There is a critical knowledge gap in current clinical practices that needs to be bridged by research data to help practitioners and patients improve their quality of care and outcomes.

This Special Issue aims to cover the various organ toxicities related to cancer therapies in the current era. This Special Issue will help to facilitate optimization in the clinical management of cancer care and to reduce symptom burden due to adverse events for cancer populations.

Original research articles and reviews are welcome in this Special Issue. Research areas may include (but are not limited to) cancer-therapy-related adverse events in different organs in relation to one or more of the following fields:

  • toxicity;
  • cardiology;
  • dermatology;
  • endocrinology;
  • gastroenterology;
  • hematology;
  • hepatology;
  • nephrology;
  • neurology;
  • ophthalmology;
  • pancreatology;
  • pulmonology;
  • rheumatology.

Dr. Yinghong Wang
Dr. Pauline Funchain
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • cancer therapy
  • toxicities
  • adverse events

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

25 pages, 1145 KiB  
Systematic Review
Elevated Likelihood of Infectious Complications Related to Oral Mucositis After Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis of Outcomes and Risk Factors
by Susan Eichhorn, Lauryn Rudin, Chidambaram Ramasamy, Ridham Varsani, Parikshit Padhi, Nour Nassour, Kapil Meleveedu, Joel B. Epstein, Benjamin Semegran, Roberto Pili and Poolakkad S. Satheeshkumar
Cancers 2025, 17(16), 2657; https://doi.org/10.3390/cancers17162657 - 14 Aug 2025
Abstract
Mucositis involving the gastrointestinal, vaginal, and nasal mucosa is one of the primary dose-limiting toxicities of hematopoietic stem cell transplantation (HSCT) and its conditioning regimen. The oropharyngeal mucosa is commonly affected, which can be detrimental to patient health and quality of life. Despite [...] Read more.
Mucositis involving the gastrointestinal, vaginal, and nasal mucosa is one of the primary dose-limiting toxicities of hematopoietic stem cell transplantation (HSCT) and its conditioning regimen. The oropharyngeal mucosa is commonly affected, which can be detrimental to patient health and quality of life. Despite its significant prevalence and deleterious effects, we have an inadequate understanding of the risk factors and outcomes associated with oral mucositis (OM). We performed a literature search through PubMed and EBSCO (inception to 31 March 2024) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data was extracted from eligible studies using a pre-specified data extraction form. Quality of the data was assessed using the Newcastle-Ottawa Scale for non-randomized, observational studies and the Cochrane Collaboration Tool for randomized controlled trials. Our initial search identified 1677 articles, 34 of which were included in our study. Of those 34, 30 were included in the qualitative assessment of clinical risk factors in the development of OM, and 4 were included in the meta-analysis assessing the relationship between OM and infectious complications following HSCT. Across both HSCT modalities and cancer cohorts, female sex and high-intensity conditioning were common risk factors in the development of OM. When stratified by allogeneic and autologous HSCT, methotrexate, younger age, and longer duration of neutropenia were associated with increased OM risk in allogeneic HSCT recipients, while renal dysfunction, HSV-1 reactivation, and longer neutrophil engraftment were associated with increased OM risk in autologous HSCT recipients. Longer neutrophil engraftment was a common risk factor across different cancer cohorts; however, renal dysfunction was a distinct risk factor for OM in multiple myeloma patients. Additionally, our meta-analysis revealed that patients with OM have an increased risk of developing infectious complications following HSCT compared to those without OM, with an odds ratio of 3.84 (95% CI: 2.51–5.86). The development of OM is related to various risk factors, and individuals with OM are at greater risk of infectious complications. Knowledge of these risk factors and outcomes will help clinicians identify high-risk individuals, prevent OM, and protect an immunocompromised population from subsequent life-threatening complications. Full article
(This article belongs to the Special Issue Cancer-Therapy-Related Adverse Events (2nd Edition))
Show Figures

Figure 1

Back to TopTop